Seth R. Blacksburg, MD, MBA, Author at Grand Rounds in Urology

Seth R. Blacksburg, MD, MBA

NYU Langone

New York, New York

Dr. Seth Blacksburg is Board Certified in Radiation Oncology and is the VP and Chief Medical Officer of the Americas at Accuray. He earned his undergraduate degree from Tufts University, where he graduated Summa Cum Laude and with the highest thesis honors. He pursued his medical degree from Duke University School of Medicine, where he also received his Masters in Business Administration with a concentration in Health Sector Management from the Duke University Fuqua School of Business. Dr. Blacksburg pursued research with the CEO and CIO of Duke University involving novel medical informatics applications. Dr. Blacksburg’s post-graduate training includes an internship in internal medicine at New York University and a residency at the Icahn School of Medicine at Mount Sinai, where he served as Chief Resident in Radiation Oncology for two years. Dr. Blacksburg continued on as faculty at Mount Sinai, where he was the first radiation oncologist selected into the Greater New York Hospital Association/United Hospital Fund Clinical Quality Fellowship. He has expertise in the treatment of genitourinary, gastrointestinal, and central nervous system tumors using innovative radiation techniques such as brachytherapy, image-guided radiation therapy (IGRT), stereotactic radiosurgery (SRS), and stereotactic body radiation therapy (SBRT). Dr. Blacksburg is a member of several professional societies and is a frequent national lecturer.

Disclosures:

Talks by Seth R. Blacksburg, MD, MBA

Hypofractionation for Prostate Cancer

Posted by Seth R. Blacksburg, MD, MBA | Sep 2018

Seth R. Blacksburg, MD, MBA, explains the rationale for hypofractionation for prostate cancer and reviews the modality’s biochemical control, toxicity, and cost-effectiveness through prospective and randomized trials. He also discusses stereotactic body radiation therapy (SBRT) as an alternative treatment option.

How Does Radiobiology Guide Dose, Fraction, and Source Selection?

Posted by Seth R. Blacksburg, MD, MBA | Aug 2018

Seth Blacksburg, MD, MBA, argues that intensity-modulated radiation therapy (IMRT), brachytherapy, hypofractionation, and stereotactic body radiotherapy (SBRT) all have similar efficacy and safety for treating low and intermediate risk prostate cancer. However, patient and physician factors impact which modality will result in optimal outcomes in individual cases.

Adjuvant or Salvage RT Post-Radical Prostatectomy

Posted by Seth R. Blacksburg, MD, MBA | Jul 2018

Seth R. Blacksburg, MD, MBA, discusses the clinical significance of biochemical failure post-radical prostatectomy (RP). He then reviews the literature regarding adjuvant and salvage radiation therapy (RT) for prostate cancer biochemical recurrence. Furthermore, he summarizes consensus guidelines, meta level considerations and debates regarding adjuvant and salvage RT, and prospective trials.